Atopy can express itself as asthma, rhinitis and eczema. The presence of atopy can be assessed by increased levels of total serum IgE and specific IgE to common allergens, skin test positivity and increased numbers of peripheral blood eosinophils. Genetic studies indicate that multiple genes are involved in the pathogenesis of atopy and that different genes regulate the presence of increased levels of serum total IgE and specific IgE. Linkage of these traits to chromosomal regions likely to contain atopic susceptibility genes has been replicated in several studies. Genome-wide screens have identified several new chromosomal locations that are likely to contain atopic genes. These regions also contain candidate genes. Moreover, the available literature suggests that multiple, yet different genes may be involved in the translation of atopy to a distinct clinical phenotype. We anticipate that understanding of the genetic basis of atopy will lead to new therapeutic interventions and early diagnosis. It has now been widely accepted that atopy constitutes a genetic disease, yet the exact genes and their loci have not been established so far. More than one gene is most likely involved in the expression of atopy and their Fig. 1 The phenotypic heterogeneity of atopy. The outer box represents a general population: approximately 40% is atopic as defined by skin test posrtivity. Allergic rhinrtis has a population prevalence of 20%. There is a considerable overlap between asthma and rhinitis; however, not all asthmatics are atopic Atopic eczema has also an overlap with asthma and allergic rhinitis. Please note that figures are estimations for a population of children and adults.
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interaction may result in different disease expressions such as asthma, rhinitis or atopic dermatitis (Fig. 1) .
The prevalence of atopy, asthma, rhinitis and atopic eczema in childhood are 40%, 10-20%, 20% and 10-20%, respectively. It has been well established that the prevalence of atopic diseases is increasing 1 . This rise in prevalence of atopy can not simply be explained by genetic factors alone, because it has occurred within one or two generations. Thus the clinical expression of the atopic trait has to be also dependent on environmental factors. Important environmental factors in the development of atopic diseases are allergen exposure, (maternal) smoking, breast feeding, Western life-style and possibly lack of infections or hygiene 2 .
Phenotypes of atopy
Atopy can be defined as a prolonged increased production of IgE as a response on exposure to common allergens. Atopy can be assessed by increased levels of total serum IgE and specific IgE to common allergens and by skin test positivity to inhalant or food allergens. Furthermore, it can be suggested that atopy is present when increased levels of peripheral blood eosinophils exist. The clinical expression of atopy includes asthma, rhinitis and dermatitis. Asthma has been defined as a chronic inflammatory disease in the airways of the lung, characterised by variable airway obstruction and airway hyper-responsiveness accompanied by symptoms such as wheeze, breathlessness or cough. Asthma generally develops in childhood, but symptoms occasionally start in adulthood. Allergic rhinitis can be defined as a recurrent or persistent inflammation of the nostrils with one or more of the following symptoms: nasal congestion, rhinorrhoea, sneezing and itching. The most common form of allergic rhinitis, i.e. hay fever, starts around the age of 7 years, but the onset can also be earlier or later in life. Atopic dermatitis is a disease most prominent in early childhood, it is characterised by an itchy red rash that has an easily broken surface.
The genetic basis of atopic disease

Family studies
It has long been known that asthma clusters in families. Until recently the route of inheritance was not known. Familial aggregation studies are the logical first step to determine the mode of inheritance. This can either be performed by twin studies or in families ascertained by a proband with the phenotype under study. Significant aggregation of asthma and atopic phenotypes in families screened by an asthmatic proband has been described 3 .
Twin studies
Twin studies are especially important to estimate both the genetic and environmental contribution to complex traits. Monozygotic (MZ) and dizygotic (DZ) twins are compared for similarities and differences between these twin types. MZ twins share 100% of their genetic information and DZ twins share 50% on average. Thus, MZ twins should resemble each other to a greater extent than DZ twins if a trait is influenced by genetic factors. The major assumptions of twin studies are that the twins are samples of the same gene pool, that they are representative of the general population, that self-reported zygosity is correct in questionnaire-based studies and that the environment for both MZ and DZ twins is similar.
Twin studies have provided evidence of a considerable genetic component of asthma, hay fever and eczema 4 ""*. Atopic phenotypes such as elevated serum total IgE and positive skin tests were studied by Hopp and co-workers and genetic contribution to both of the phenotypes was suggested 7 . Table 1 provides an overview on atopic twin studies and shows that atopy itself (IgE and positive skin test) is genetically determined as well as asthma, rhinitis and eczema (modified table, references from review article by Los et al. 8 ). Heritability lies in general between 0.60 and 0.70 and monozygotic twins have always a higher concordance of the trait under study than dizygotic twins.
Segregation analyses
Segregation analyses are used to model inheritance patterns in families. The distribution of a disease is studied in families and the observed frequency of the disorder in offspring and siblings is compared to the expected distribution using different genetic models of inheritance (e.g. dominant, co-dominant, recessive or polygenic).
Different genetic models have been found for total serum IgE. Several explanations may be given for these different findings. The first explanation may be the variable definition of atopy between studies. Secondly, the ascertainment of families for segregation studies may play a role. In families screened for asthma, estimates on frequencies of alleles regulating total serum IgE are expected to be higher than in families sampled randomly from the general population. A final explanation may be genetic heterogeneity. This means that in different populations, separate genes act in the regulation of these phenotypes. To date, this cannot be investigated since the exact locations of these genes are still unknown. Using a single locus approach, the best fitting models for high serum IgE levels were the models of a major Mendelian gene, either codominant, recessive, mixed model of recessive inheritance, dominant, or in two other studies of polygenic inheritance. In a study of 243 Australian nuclear families, evidence for recessive inheritance of total serum IgE and significant residual familial correlations were found 9 . However, these correlations were not significant when the presence of the specific immune response was accounted for in the analysis. Therefore, it suggests that regulation of total serum IgE is genetically independent from the regulation of allergen specific IgE. A two locus model on IgE in 92 Dutch families screened through a proband with asthma provided a significantly better fit of the data than a one-locus model 10 . In addition, evidence was presented for two unlinked loci regulating total serum IgE in these families. The first locus alone explained 50.6% of the variance of the level of total serum IgE, the second 19%. Considered jointly, the two loci accounted for 78.4% of the variability of total serum IgE. No data on the segregation of skin test positivity or specific IgE levels to allergens as a representative for atopy have been presented so far.
In the European Community Respiratory Health Survey of 13,963 asthma patients, the complex segregation analysis of the asthma phenotype provides evidence for a two-allele gene with co-dominant inheritance 11 . Other studies on aggregation of asthma and wheeze in families are summarised in Table 2 (for references see the review article by Los et al. s ). The segregation of asthma in these families appears to be predominantly consistent with the action of multiple genes with a small effect.
In summary, segregation analyses of asthma or atopy, when expressed as total serum IgE, confirms a genetic trait, but the mode of inheritance is yet uncertain as are the number of genes involved. There are no data available on eczema and rhinitis.
Linkage
Linkage analysis is used to determine a chromosomal region which cosegregates with a certain trait within families. The likelihood that a trait co-segregates with a marker is expressed as a LOD score, i.e. the log of the ratio of the likelihood of linkage and the likelihood of no linkage. A value of +3 is traditionally taken as evidence for linkage and a value of -2 is considered evidence against linkage. Linkage analysis requires pedigree data as opposed to association studies in which unrelated cases and controls are needed. To study linkage using the LOD score approach, a genetic model has to be specified for different parameters such as mode of inheritance, allele frequencies and penetrance. Sometimes these parameters can be estimated from segregation analyses, which is preferable; but, in most cases, the parameters are not known.
No specification of a genetic model is needed in non-parametric approaches such as the sibling pair analysis and affected relative pair analysis. These methods test whether the inheritance of a chromosomal region is not consistent with random segregation. If this is the case, affected relatives inherit identical copies of alleles in this region more often than would be expected by chance 12 . The observed and expected distributions of alleles can be tested with a x 2 -test. In general, evidence for linkage is assumed to be present when the reviewed linkage from one study has been replicated by others.
Identifying atopic disease genes
In identifying genes there are two general approaches. In the genomewide screen all chromosomes are searched until the approximate location of the gene is discovered. The localisation of the gene is progressively refined until the gene itself is isolated by linking the inheritance of specific chromosomal regions with the inheritance of disease. This approach is often referred to as positional cloning. The candidate gene approach is used when a gene is a plausible candidate for being the disease gene because of its function. The strategy is to find polymorphisms in a known gene and to compare the frequency of alleles in cases and controls. The finding of a positive association of an allele and a trait can be interpreted in three ways 12 : (i) the allele of interest is the relevant mutation in the disease gene; (ii) the allele is in linkage disequilibrium, which means that it is physically very close to the gene; or (iii) the association is a result of population admixture. This occurs if a certain trait has a higher prevalence in an ethnic subgroup within a mixed population. Any allele with a higher frequency within this subgroup will show association with the trait.
Genome-wide search
Recently, genome-wide searches have contributed significantly to the mapping of atopic genes by conducting searches in different human populations. Families were recruited in Western Australia, Sweden, Germany, The Netherlands and from the US (both African Americans, Caucasians, Hispanics and Hutterites) 3 ' 13 . Evidence for linkage to multiple chromosomal regions was reported in each study. Linkage by multiple groups were found on chromosomes 1,2q, 3,4, 5q, 6p, 7, 9, llq, 12q, 13q, 14,16 and 17q. 'Novel' regions of interest are 17p, 19 and 21 because they were only observed in one study. Table 3 shows the replicated linkages on the different atopic traits. Genome-wide screens show many regions of interest, but just a few linkages have been replicated.
Linkage and association of atopy
Atopy
Linkage for atopy (broadly defined) was found on chromosome 5, 6, 11, 13. Only the linkage to chromosome 11 has been replicated. Cookson and co-workers reported linkage of a broadly defined atopic phenotype to markers on chromosome llq 14 . Seven families were studied, and most of the LOD score was contributed by one single family using an autosomal dominant mode of inheritance. The investigators confirmed their findings in other samples. In addition, other studies from The Netherlands, Germany, Japan and Australia found evidence for linkage between an atopic phenotype and markers on chromosome llq 8 . Sequence variants in the highaffinity IgE receptor (FceR) gene on chromosome 11 may increase the risk for development of atopy 3 . Linkage of chromosome llq to atopy and asthma remains controversial due to multiple failures to replicate the linkage in several other populations. Subsequent work of Cookson et al. suggested that the linkage in other studies may have been obscured by maternal inheritance 15 . Possible explanations for maternal inheritance of atopy are paternal imprinting (a process by which a particular gene is differentially activated or silenced, depending on the sex of the parent from whom it was inherited) or maternal modification of the developing immune response.
Total serum IgE
Linkage of total serum IgE to chromosomes 1, 2, 4, 5, 6, 7, 9, 11, 12, 13, 14, 15 and 16 has been found by several research groups. Replication of significant linkage has been found to chromosomes 5, 11 and 12.
In 199A, Marsh et al. were the first to report linkage between serum total IgE levels and chromosome 5q in an American Amish population 16 . Meyers et al. replicated this finding in a study of Dutch families 17 . More studies have replicated linkages on chromosome 5 whereas others could not 8 . This can be due to different populations, definitions of phenotypes, founder effects, admixture, and possibly varying environmental influences.
Specific IgE
Linkage for specific IgE has been found to chromosomes 1, 2, 4, 6, 7, 9, and 12. There is only limited data available with regard to linkage of specific IgE to particular chromosomal regions. Most linkages are not significant, i.e. they do not reach the maximum LOD score of 3. Furthermore, significancies are very low. Summary of the available literature shows that the required replication of linkage to a chromosomal area is still not found.
Skin prick test
Linkage for skin prick tests was found on chromosomes 1, 3, 6, 9, 11 and 16. Replication of linkage of a positive skin prick test existed for chromosomes 1 and 11. Ober was the first to investigate skin prick tests as an atopic phenotype by itself 13 . Other investigators have always used a composite score of atopy, including skin prick test.
Peripheral blood eosinophilia
Linkage for peripheral blood eosinophilia was reported on chromosomes 1, 3, 4, 5, 6, 7, 11, 14 and 16. Linkage of eosinophilia to chromosome 6 is significant and has been replicated.
Asthma
Linkage for asthma was found on chromosomes 1, 2, 3, 5, 6, 9,11-14,17, 19 and 21. Evidence for linkage and association for both asthma and total IgE to chromosome 12q was reported in an Afro-Caribbean population 18 . Other studies confirmed a linkage for IgE or asthma on chromosome 12q. An interesting finding is that the chromosomal regions on 12q implicated in these studies are not exactly the same 3 . Further studies are needed to fine map this region and may answer the question whether one or more regions on 12q are implicated in asthma and atopy.
Several candidate genes map to this wide region such as interferongamma, IGF1 (promotes differentiation of both B and T lymphocytes), a mast cell growth factor and the P-subunit of nuclear factor-Y (possibly upregulating transcription of both EL-4 and the HLA genes). For references, see Wiesch et aP.
Atopic eczema
Linkage of atopic eczema (AE) has been reported on chromosome 5q31 19 . There are only a few genetic studies on atopic eczema. Shirwaka et al. confirmed the association between FceRIp on chromosome Ilql3 and atopy underlying AE (for references see Tanaka and co-workers 20 ). Significant association of AE and mast-cell chymase (MCC; a serine protease secreted by skin mast cells) on 14qll has also been reported 21 . Recently, an association between AE and a functional mutation in the promoter region of the C-C chemokine RANTES was found in children from Germany 22 .
Allergic rhinitis
No reports are available about linkage of allergic rhinitis.
Asthma and atopy genes
When reviewing the literature there are some interesting and promising polymorphisms in genes related to atopy, for instance the CD 14 polymorphism, IL-4, IL-13 and p 2 -receptor.
CD14 IL-4and IL-13
The CD 14 gene is located on chromosome 5q31, expressed on the surface of macrophages and monocytes, and is also present in serum in a soluble form (sCD14). CD14 is an important high affinity receptor for lipopolysaccharide (LPS) and other bacterial wall products. LPS exposition by bacterial infections in infancy may shift the Th-l/Th-2 balance in favour of Th-1 type immune response, thereby suppressing the Th-2 response, which leads to atopy There are many candidate genes for atopy on chromosome 5q, such as a cluster of cytokine genes IL-3, IL-4, IL-5, IL-9 and IL-13. These cytokines are mediators of inflammation in atopy; IL-4 is an important mediator in regulating the production of IgE and skewing the Th-l/Th-2 balance to Th-2. IL-13 acts on B-cells to produce IgE and there is increasing evidence that IL-13 is crucial in inducing asthma in animal models (for references see Shirakawa et al. 25 ). Five variants have been reported in the IL-4 promoter region, four of them being very rare. Recently, two variants of IL-13 have been identified, a promoter polymorphism associated with increased risk of allergic asthma as well as a coding variant (glnllOarg) of IL-13 that is associated with both atopic and non-atopic asthma in a British and a Japanese population 25 . IL-4 and IL-13 operate through the IL-4 and IL-13 receptor, both receptors share the IL-4Ra chain 25 . IL-4 binds to both types of receptors through the IL-4Ra chain, whereas IL-13 can bind only to the IL-13 receptor. The IL-4 receptor can be expressed on both B-and T-cells, the IL-13 receptor only on B-cells. Thus, IL-4 can stimulate both B-and Tcells, whereas IL-13 can activate B-cells only. Both receptors activate STAT6 (signal transducer and activator of transcription 6), the IL4Ra-STAT6 interaction is essential for IL-4 and IL-13 signalling. STAT6 induces GATA3 activation and enables Th-2 cells to maintain their Th-2 characteristics, while inducing B-cells to produce IgE. Therefore, the observation that polymorphisms in these genes are associated with asthma has important implications for both the understanding of asthma and the possibility of devising new strategies for prevention or amelioration of the disease. Finally, a strong linkage has been found between atopy and flanking markers to IL-4R on chromosome 16pl2. $ 2 -Adrenergic receptor P 2 -Adrenergic receptors are localised on airway smooth muscle, epithelium and inflammatory cells (mast cells, macrophages, eosinophils and T-lymphocytes). P 2 -Adrenergic receptor function is mainly regulated by circulating epinephrine and mediates most of the effects of (3 2 -agonists on airway function. The P 2 -adrenergic receptor (P 2 AR) gene is localised on chromosome 5q 31-32. This gene is intronless and has a coding block consisting of 1239 nucleic acids. Nine known polymorphisms varying within the normal population are situated in this region, and four polymorphisms result in amino acids variations on positions 16, 27, 34, and 164. One polymorphism has been identified in the 5' leader cistron sequence, a peptide that modifies P 2 AR translation. Although no differences in the polymorphism frequencies were found in asthmatics compared with non-asthmatic controls, cell and transgenic mouse studies have shown altered function or regulation of the P 2 AR (for references see Liggett 26 ). Two variants may play a role in asthma treatment. The first is the glyl6 variant which is a common polymorphism in the general population. Tan and co-workers reported that homozygous individuals with this variant showed reduced treatment response following either acute or chronic exposure to P 2 -agonists. Secondly, ilel64 is an example of a rare polymorphism, which may be important since in vitro functional studies have demonstrated that the ilel64 receptor has an approximately 3-fold decreased affinity for P 2 -agonists. P 2 AR polymorphisms can have a pharmacogenetic effect or act as disease-modifiers. For instance, P 2 -adrenergic receptor associations have been found with nocturnal asthma, bronchial hyper-responsiveness, increased IgE levels, and asthma severity.
5-Lipoxygenase
The core promotor of the 5-lipoxygenase (ALOX5) gene is localised on chromosome 10qll.2 27 . The level of ALOX5 activity determines to a. certain extent the level of bronchoconstrictor leukotrienes in the airways. This gene is the first to provide evidence that pharmacogenetics can be applied to asthma. One study showed that The ALOX5 locus contains 3-6 tandem repeats of the Spl-binding motif GGGCGG. Asthma patients without the wild type (5 tandem repeats) allele do not improve or improve to a smaller extent when treated with a drug which mechanism of action is the inhibition of AL0X5. Thus treatment response is to a certain extent determined by genetic variants in the 5-lipoxygenase gene.
Implications of results of the available studies and future directions
Atopy has different disease expressions such as asthma, rhinitis and eczema which all have been shown to contain a significant genetic contribution. The available literature shows that linkage of the different measures of atopy are found on distinct chromosomes. Whereas replicated linkage exists on chromosome 11 for a broadly defined atopy phenotype, for total serum IgE and skin prick tests, this is not the case for specific IgE. Linkage of total serum IgE has been replicated for chromosomes 4-7, yet no linkage whatsoever or no replication has been found for specific IgE or skin prick test. Thus, either different genes are to be involved in the regulation of total IgE and allergen specific responses or one (or more) gene may interact with the environment or both. Furthermore, distinct combinations of genes may result in different disease expressions such as asthma, rhinitis and atopic dermatitis. For instance it is hypothetical, but not totally improbable, that genes for atopy and airway hyper-responsiveness are to be present in case of the clinical expression of asthma, yet the latter genes are not mandatory for eczema (or even rhinitis).
Several candidate genes have been identified, yet more atopic genes are to be discovered in the future. These genes will give us more insight of the pathophysiological mechanisms of atopic disease. It can be expected that this will lead to new and more effective therapeutic interventions, new methods for early diagnosis, development for disease prevention in susceptible individuals and more insight in the pharmacogenetics.
